Qiagen announced the FDA clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States. This assay is designed for direct detection of asymptomatic and symptomatic bacterial infections involving Chlamydia trachomatis, or CT, and / or Neisseria gonorrhoeae, or NG – the most common type of bacterial infection among sexually transmitted infections, according to the U.S. National Institutes of Health.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on QGEN:
- QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems
- QIAGEN announces plans to return approximately $300 million to shareholders
- QIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business
- QIAGEN expands business in Middle East with new regional headquarters and major projects
- Qiagen initiated with an Equal Weight at Wells Fargo
